Monitor

  • PharmaTag monitors critical drugs during transportation

    European based company Dyzle (www.Dyzle.com) is launching its new leading edge solution for the pharmaceutical industry – the PharmaTag. The approach is simple: a thin measuring device, the size of a credit card, travels with the product during its…

    Monitor | 07 September 2011

  • IKS introduces low cost route to high quality laboratory monitoring

    IKS International’s XiltrixLite packages provide a low cost, easy introduction to laboratory monitoring with savings of up to 25 percent compared with systems configured from individual modules. With these fully integrated packages, installation a…

    Monitor | 07 January 2011

  • Pharma enhances its focus on Asia-Pacific partnerships

    Datamonitor ’s report “Pharmaceutical Licensing and Alliances in the Asia-Pacific Region”, published in November 2010, reveals that pharma is enhancing its focus on markets in the APAC region. The largest of the developed APAC markets, Jap…

    Monitor | 24 November 2010

  • Chinese diabetic population is rising

    Yifu Liu, Datamonitor ’s healthcare analyst, gives an expert analysis on China’s diabetic population. According to a statement released by the Chinese health authority, nearly one out of 10 people in China suffers from diabetes, leading to C…

    Monitor | 23 November 2010

  • Market development key for testosterone replacement therapy

    Despite growing at a compound annual growth rate of more than 24 percent over the last five years, the testosterone replacement therapy market is severely underdeveloped. Datamonitor , an independent market analyst, said that this suggests there are …

    Monitor | 23 November 2010

  • Constant innovation in Australian biotech

    Dr Bornadata (Bonnie) Bain, global director of healthcare research and analysis, Datamonitor comments: “Pharma’s continued need to restock pipelines in order to secure future growth—in the face of ongoing patent expiries—maintains ongoi…

    Monitor | 09 November 2010

  • Pfizer is acquiring King Pharmaceuticals

    Expert comment from Datamonitor principal analyst Simon King: “The King acquisition represents a small but integral part of a broader diversification strategy that continues to be implemented by Pfizer. This strategy has to date encompassed th…

    Monitor | 09 November 2010

  • Biosimilars in Australia: Nivestim

    Expert comment from Lisette Oversteegen, lead analyst, Datamonitor . Compared with Europe, where several biosimilar products of three different molecules (epoetin, filgrastim and somatropin) have been approved since 2006, Australia’s biosimilars…

    Monitor | 22 October 2010

  • Australia considers Victoza for reimbursement

    Expert comment from Lisette Oversteegen, lead analyst, Datamonitor : “In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza f…

    Monitor | 21 October 2010

  • Bigger market share for RA biologic treatments

    Use of biologic disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis is set to increase dramatically over the next five years, says independent market analyst Datamonitor . Despite their considerable cost, rheum…

    Monitor | 15 October 2010

Page 1 Next > Last >>